Pete Hegseth, the Secretary of Veterans Affairs, is promoting testosterone treatment for veterans, but the VA's track record with the therapy reveals substantial operational and medical challenges.
The VA has encountered difficulties managing testosterone prescriptions and monitoring patient outcomes. Medical experts warn that testosterone treatment carries risks including reduced sperm counts, yet the department lacks clear protocols for long-term patient follow-up care. One medical professor emphasized the fertility concerns: "Men who take testosterone will have a reduction in their sperm counts."
Hegseth's push for expanded testosterone access reflects a broader conservative emphasis on masculinity and veteran health, but the timing raises questions about implementation capacity. The VA already struggles with basic care coordination for existing treatments. Adding testosterone therapy without resolving these systemic gaps could strain resources and compromise patient safety.
The core issue centers on continuity of care. Testosterone treatment requires regular monitoring for side effects, dosage adjustments, and screening for contraindications. The VA has not articulated a comprehensive plan for these ongoing requirements. Veterans starting treatment need blood work, cardiovascular screening, and prostate monitoring, yet the department's current infrastructure remains inadequate for such sustained engagement.
Medical literature documents risks beyond infertility, including increased cardiovascular events, sleep apnea exacerbation, and mood changes. Without robust monitoring systems, these complications could go undetected in veteran populations already dealing with service-related health conditions.
Hegseth's initiative also raises questions about equity and appropriateness. Testosterone therapy addresses specific medical conditions, primarily hypogonadism, but expanding access without clear clinical criteria risks treating normal aging as disease. The VA must balance veteran preferences against sound medical practice.
The gap between policy ambition and operational reality remains stark. Before expanding testosterone access, the VA needs functional systems for patient screening, informed consent, baseline testing, and ongoing monitoring. Without these foundations, even well-intentioned policy creates